These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38448887)

  • 1. Peritoneal dialysis vs. hemodialysis among patients with end-stage renal disease in Iran: which is more cost-effective?
    Yousefi M; Rezaei S; Hajebrahimi S; Falsafi N; Keshvari-Shad F
    BMC Nephrol; 2024 Mar; 25(1):85. PubMed ID: 38448887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
    Wong CKH; Chen J; Fung SKS; Mok M; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
    BMC Nephrol; 2020 Feb; 21(1):42. PubMed ID: 32019528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
    Yang F; Lau T; Luo N
    Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
    Teerawattananon Y; Mugford M; Tangcharoensathien V
    Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of renal replacement therapy strategies in Guangzhou city, southern China.
    Yang F; Liao M; Wang P; Liu Y
    BMJ Open; 2021 Feb; 11(2):e039653. PubMed ID: 33550227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial implications of dialysis modalities in the developing world: A Chinese perspective.
    Liu J; Hutton DW; Gu Y; Hu Y; Li Y; Ma L; Zeng X; Fu P
    Perit Dial Int; 2020 Mar; 40(2):193-201. PubMed ID: 32063196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of peritoneal dialysis and hemodialysis in Thai population with End-stage Kidney Disease.
    Assanatham M; Pattanaprateep O; Chuasuwan A; Vareesangthip K; Supasyndh O; Lumpaopong A; Susantitaphong P; Limkunakul C; Ponthongmak W; Chaiyakittisopon K; Thakkinstian A; Ingsathit A
    BMC Health Serv Res; 2022 Nov; 22(1):1384. PubMed ID: 36411422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of three dialysis methods in patients with end-stage renal disease in China.
    Hong Z; Zhuang Y; Lu J; Ye J; Sun H; Gao L; Xiong Y
    Int Urol Nephrol; 2023 May; 55(5):1247-1254. PubMed ID: 36376531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Utility Analysis of Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis for Thai Patients With End-Stage Renal Disease.
    Thaweethamcharoen T; Sritippayawan S; Noparatayaporn P; Aiyasanon N
    Value Health Reg Issues; 2020 May; 21():181-187. PubMed ID: 32044691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia.
    Afiatin ; Khoe LC; Kristin E; Masytoh LS; Herlinawaty E; Werayingyong P; Nadjib M; Sastroasmoro S; Teerawattananon Y
    PLoS One; 2017; 12(5):e0177436. PubMed ID: 28545094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.
    Surendra NK; Abdul Manaf MR; Hooi LS; Bavanandan S; Mohamad Nor FS; Firdaus Khan SS; Meng OL; Abdul Gafor AH
    PLoS One; 2019; 14(10):e0218422. PubMed ID: 31644577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis.
    Wong CKH; Chen J; Fung SKS; Mok MMY; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
    Nephrol Dial Transplant; 2019 Sep; 34(9):1565-1576. PubMed ID: 30668781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation.
    Yousefi M; Rezaei S; Khoshbaten M; Sarmasti M
    Helicobacter; 2023 Dec; 28(6):e13027. PubMed ID: 37839058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.
    Zhang H; Zhang C; Zhu S; Ye H; Zhang D
    BMC Health Serv Res; 2020 Feb; 20(1):122. PubMed ID: 32059726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More Use of Peritoneal Dialysis Gives Significant Savings: A Systematic Review and Health Economic Decision Model.
    Pike E; Hamidi V; Ringerike T; Wisloff T; Klemp M
    J Clin Med Res; 2017 Feb; 9(2):104-116. PubMed ID: 28090226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden and cost-utility analysis of three renal replacement therapies in ESRD patients from Yunnan Province, China.
    Wu H; Li Q; Cai Y; Zhang J; Cui W; Zhou Z
    Int Urol Nephrol; 2020 Mar; 52(3):573-579. PubMed ID: 32009220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective.
    Treharne C; Liu FX; Arici M; Crowe L; Farooqui U
    Appl Health Econ Health Policy; 2014 Aug; 12(4):409-20. PubMed ID: 25017433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score.
    Chang YT; Hwang JS; Hung SY; Tsai MS; Wu JL; Sung JM; Wang JD
    Sci Rep; 2016 Jul; 6():30266. PubMed ID: 27461186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Filtering for the best policy: An economic evaluation of policy options for kidney replacement coverage in the Philippines.
    Bayani DBS; Almirol BJQ; Uy GDC; Taneo MJS; Danguilan RS; Arakama MI; Lamban AB; de Leon D; Pamugas GEP; Luz AC; Teerawatananon Y
    Nephrology (Carlton); 2021 Feb; 26(2):170-177. PubMed ID: 33207027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.